1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

SynAct Pharma management and Chairman of the Board have acquired shares

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the CEO, CSO, CBO, and the Chairman of the Board have acquired shares in the company.

Specifically, the Chairman of the Board, Anders Kronborg has acquired 3,470 shares, the CEO Jeppe Øvlesen, CSO Thomas Jonassen, and CBO Mads Bjerregaard, have acquired 8,558 shares. Total of 12,028 shares.

“We are close to finalizing recruitment on our lead program in Rheumatoid Arthritis, and we are ready to initiate trial in viral infection. We are looking forward to an exciting 2026 with a strong team and upcoming key data. It is a pleasure to see the strong commitment in the management group and to have the support of our board,” said CEO Jeppe Øvlesen.

The purchases were made on Nasdaq OMX Stockholm.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
SynAct Pharma management and Chairman of the Board have acquired shares

Datum 2025-12-22, kl 08:00
Källa MFN
Bifogade filer
SynAct Pharma management and Chairman of the Board have acquired shares